Read more here:
http://www.investopedia.com/
Showing posts with label Medicis. Show all posts
Showing posts with label Medicis. Show all posts
Friday, September 7, 2012
Investopedia: Valeant Works Its Mojo With Medicis
It seems pretty obvious that once a company figures out a winning formula, it ought to stick with it. Acquisitions have definitely done a lot to build and boost specialty pharmaceutical company Valeant (NYSE:VRX). Now the company is going to the well again to acquire Medicis (NYSE:MRX).
While there's always a risk that Valeant will eventually bite off more
than it can chew, this deal looks like a winner from the get-go.
Read more here:
http://www.investopedia.com/
Read more here:
http://www.investopedia.com/
Friday, June 29, 2012
Investopedia: Can Body Sculpting Bulk Up Solta Medical?
Most investors are probably aware that the healthcare industry slowed
significantly during the recession and has been very slow in coming
back. Hospitals have pulled back on capital spending
and procedure counts have dropped as would-be patients worry about
inadequate insurance coverage, higher co-pays and/or the opportunity to
take time off for recuperation.
There's another segment of the healthcare industry, though; one built around elective procedures that is generally not covered by health insurance. Aesthetics is a big part of this segment, and the market for skin tightening, rejuvenation and so on nearly collapsed in the recession. Procedure counts are starting to come back, though, and Solta Medical (Nasdaq:SLTM) is a risky name worth checking out by virtue of its differentiated business model and new LipoSonix body-sculpting line.
Follow this link for more:
http://stocks.investopedia.
There's another segment of the healthcare industry, though; one built around elective procedures that is generally not covered by health insurance. Aesthetics is a big part of this segment, and the market for skin tightening, rejuvenation and so on nearly collapsed in the recession. Procedure counts are starting to come back, though, and Solta Medical (Nasdaq:SLTM) is a risky name worth checking out by virtue of its differentiated business model and new LipoSonix body-sculpting line.
Follow this link for more:
http://stocks.investopedia.
Monday, April 16, 2012
Seeking Alpha: Shedding A Little Light On Under-Followed DUSA Pharmaceuticals
There are certain dusty corners of biopharma where most investors just don't look all that often, and eye care and skin care are high on the list. While the addressable markets are well short of what investors expect from areas like oncology or autoimmune disease, the relative lack of competition can make these profitable niches. As under-followed ISTA Pharmaceuticals (ISTA) recently rode a limited roster of products to a worthwhile takeout price, investors may want to consider DUSA Pharmaceuticals (DUSA) for similar potential.
Read more here:
Shedding A Little Light On Under-Followed DUSA Pahrmaceuticals
Read more here:
Shedding A Little Light On Under-Followed DUSA Pahrmaceuticals
Wednesday, March 28, 2012
Seeking Alpha: Auxilium Pharmaceutiacls Has The Approvals; Can It Get The Revenue?
FDA approval is undoubtedly a major event in the life of a biotech company, but it is only a part of the puzzle. Marketing an approved drug is a battle in its own right, as investors in Auxilium Pharmaceuticals (AUXL) know all too well.
The company has found it difficult to drive market acceptance of its Testim testosterone gel and Xiaflex injection for Dupuytren's contracture and expectations have come down markedly. While the company's current products could still have billion-dollar potential, investors need to be prepared for a long, difficult slog to realize that potential.
Read the full article here:
Auxilium Pharmaceuticals Has The Approvals; Can It Get The Revenue?
The company has found it difficult to drive market acceptance of its Testim testosterone gel and Xiaflex injection for Dupuytren's contracture and expectations have come down markedly. While the company's current products could still have billion-dollar potential, investors need to be prepared for a long, difficult slog to realize that potential.
Read the full article here:
Auxilium Pharmaceuticals Has The Approvals; Can It Get The Revenue?
Thursday, January 19, 2012
Seeking Alpha: Patience With Palomar Could Pay
Few sectors of healthcare have been gutted to the same extent as aesthetics. Although large players with more of a pharmaceutical focus like Allergan (AGN) and Medicis (MRX) have held up reasonably well, that is in large part because a larger part of their business falls under the header of "medically necessary" and is eligible for insurance reimbursement.
For the device companies, particularly the energy-based device (colloquially called "lasers") companies, though, it has been a hard road indeed. While procedure volume has not yet picked up significantly, investors looking for to get in early may want to consider Palomar Medical Technologies (PMTI). If a recovery in aesthetics procedures really is a "sooner or later" event, the low valuation and strong IP could make this an interesting stock again.
Please follow this link:
Patience With Palomar Could Pay
For the device companies, particularly the energy-based device (colloquially called "lasers") companies, though, it has been a hard road indeed. While procedure volume has not yet picked up significantly, investors looking for to get in early may want to consider Palomar Medical Technologies (PMTI). If a recovery in aesthetics procedures really is a "sooner or later" event, the low valuation and strong IP could make this an interesting stock again.
Please follow this link:
Patience With Palomar Could Pay
Thursday, November 10, 2011
Investopedia: Medicis May Not Stay Independent
There are a lot of interesting talking points to take from Medicis Pharmaceutical's (NYSE:MRX) latest earnings report. The company certainly does deserve praise for how it has managed potential generic threats to Solodyn, as well as arguably maximizing what it could from its LipoSonix business. Looking ahead, there is certainly the possibility that Medicis can become a more formidable competitor to Allergan (NYSE:AGN), but shareholders may want to consider the likelihood that Medicis will be folded into a larger pharmaceutical company in the not-so-distant future.
So-So Results for the Third Quarter
Although there was no glaring problem area for Medicis, this quarter, it was still not all that strong. Revenue rose about 4%, and came in basically at the bottom end of the range. Growth in the core acne business was light (below 1%), while non-acne revenue rose 12% on strong unit sales of Restylane and Dysport.
Read more here:
http://stocks.investopedia.
So-So Results for the Third Quarter
Although there was no glaring problem area for Medicis, this quarter, it was still not all that strong. Revenue rose about 4%, and came in basically at the bottom end of the range. Growth in the core acne business was light (below 1%), while non-acne revenue rose 12% on strong unit sales of Restylane and Dysport.
Read more here:
http://stocks.investopedia.
Wednesday, March 2, 2011
Investopedia: Medicis - Generic Reprieve and Shareholder Relief
Medicis (NYSE:MRX) shareholders got a big bonus with the company's latest earnings release. With generic competition for the company's key drug, Solodyn, looming, the company announced a settlement with Teva (Nasdaq:TEVA) that will postpone its entry for several years and further shield the company's key franchise. While generic competition will still come in November of this year, the company has used line extensions and settlements to shield upwards of 80% of its revenue for many years. No wonder, then, that the stock was up strongly in Monday's trading.
A Quarter That's Almost an Afterthought
Lucky for Medicis that they had good news to report on the non-operating front, as the company's fourth quarter earnings were not likely to excite investors all that much. Revenue rose 2% but slightly missed the average expectation. Core acne product revenue dropped 10%, though due in part to planned product discontinuations. Non-acne revenue jumped 34%, largely on the backs of Dysport (botulinum toxin) and Restylane (a dermal filler).
While revenue performance was so-so, the profitability side of things was even more so. Gross margin did improve almost a full point in the quarter, but very sizable spending increases in SG&A and R&D led to a decline in operating income (even when excluding an impairment charge). Still, a lot of this was already in the models of Medicis' analysts and the company met its EPS estimate for the period.
Please click this link for the full piece:
http://stocks.investopedia.
A Quarter That's Almost an Afterthought
Lucky for Medicis that they had good news to report on the non-operating front, as the company's fourth quarter earnings were not likely to excite investors all that much. Revenue rose 2% but slightly missed the average expectation. Core acne product revenue dropped 10%, though due in part to planned product discontinuations. Non-acne revenue jumped 34%, largely on the backs of Dysport (botulinum toxin) and Restylane (a dermal filler).
While revenue performance was so-so, the profitability side of things was even more so. Gross margin did improve almost a full point in the quarter, but very sizable spending increases in SG&A and R&D led to a decline in operating income (even when excluding an impairment charge). Still, a lot of this was already in the models of Medicis' analysts and the company met its EPS estimate for the period.
Please click this link for the full piece:
http://stocks.investopedia.
Wednesday, November 3, 2010
Allergan Winning Wall Street's Beauty Pageant
These are rough times for the medical world. Major pharmaceutical companies like Pfizer (NYSE:PFE) and Lilly (NYSE:LLY) and prominent device companies like Medtronic (NYSE:MDT) and Covidien (NYSE:COV) are limping and wheezing as investors worry about growth prospects in a tough economy and an even tougher FDA.
It would be reasonable to think that if these companies (that are largely protected by serving legitimate medical needs and getting full reimbursement from health insurance) are struggling, a company with more exposure to elective and self-pay products would be in even worse shape. Well, that does not seem to be the case for Allergan (NYSE:AGN). Although Allergan is seeing a hit to growth, Wall Street still seems smitten with this largely cosmetic-oriented company.
A Saggy (But Positive) Quarter
Allergan did manage to surpass the consensus expectations for the third quarter. Product sales rose almost 6% on an as-reported basis, with pharmaceutical sales growing more than 5% and device sales up more than 8% (both were higher on an ex-currency basis). Allergan foresees solid growth in its pharmaceutical portfolio (from drugs like Restasis and Lumigan) and Botox was up more than 4%, despite competition from Medicis (NYSE:MRX).
Allergan did manage to surpass the consensus expectations for the third quarter. Product sales rose almost 6% on an as-reported basis, with pharmaceutical sales growing more than 5% and device sales up more than 8% (both were higher on an ex-currency basis). Allergan foresees solid growth in its pharmaceutical portfolio (from drugs like Restasis and Lumigan) and Botox was up more than 4%, despite competition from Medicis (NYSE:MRX).
Please click the link to read the full piece at Investopedia:
http://stocks.investopedia.
Friday, September 3, 2010
Waiting For A Rebound In Vanity
I have seen it written that you cannot put a price on beauty. The performance of stocks in the aesthetics sector would seem to suggest otherwise. As the housing bubble exploded, the economy fell into recession, credit suddenly became tight, and people stopped finding the money to pay for all manner of personal exterior renovations. (For related reading, take a look at Lipstick And The Stock Market: Connection?)
If it is true that whatever goes up must come down, can it also be true that a sector laid low by a punishing reduction in disposable income and easy credit could rebound again? Since people do not really change all that quickly, it seems reasonable to assume that the demand for cosmetic procedures is still out there and that when disposable income rebounds, so too will this sector.
To read the full piece:
http://stocks.investopedia.
If it is true that whatever goes up must come down, can it also be true that a sector laid low by a punishing reduction in disposable income and easy credit could rebound again? Since people do not really change all that quickly, it seems reasonable to assume that the demand for cosmetic procedures is still out there and that when disposable income rebounds, so too will this sector.
To read the full piece:
http://stocks.investopedia.
Subscribe to:
Posts (Atom)